Norgine’s PEDMARQSI Approved in Australia for Child Cancer Patients

Norgine Secures Major Win with Australian Regulatory Approval for Hearing Loss Prevention

In a significant development for pediatric oncology, pharmaceutical company Norgine has announced the Therapeutic Goods Administration (TGA) approval of PEDMARQSI® (sodium thiosulfate anhydrous) in Australia. The drug represents a meaningful advancement in protecting children from one of chemotherapy’s most debilitating side effects: hearing loss induced by cisplatin treatment.

The TGA registration covers the use of PEDMARQSI® for preventing ototoxicity—a condition where chemotherapy damages the inner ear—in patients ranging from 1 month to under 18 years of age who are being treated for localized, non-metastatic solid tumors. This approval marks a watershed moment for families facing the difficult choice between aggressive cancer treatment and the risk of permanent auditory damage in their children.

Addressing a Long-Overlooked Medical Challenge

For decades, cisplatin has remained one of the most effective chemotherapy agents in the oncologist’s arsenal, particularly for treating pediatric cancers. However, its efficacy comes with a steep price: a substantial proportion of young patients experience hearing loss as a direct consequence of treatment. This ototoxicity can range from mild high-frequency hearing impairment to profound deafness, fundamentally affecting a child’s speech development, educational outcomes, and social integration during critical formative years.

The absence of an approved preventative treatment has left clinicians and families in an untenable position. While doctors could monitor hearing and implement supportive measures, they had no pharmaceutical intervention to mitigate the damage occurring at the cellular level during chemotherapy administration. This represented a significant unmet medical need—one that has frustrated pediatric oncologists and devastated families confronting the reality of their child’s potential permanent disability.

How PEDMARQSI® Changes the Treatment Landscape

PEDMARQSI® works by functioning as a cytoprotective agent, essentially shielding the delicate structures within the inner ear from cisplatin’s toxic effects. By administering sodium thiosulfate anhydrous alongside chemotherapy, clinicians can now offer families a concrete strategy for preventing hearing damage while maintaining the cancer-fighting efficacy of cisplatin treatment.

The TGA’s decision to register PEDMARQSI® reflects a rigorous evaluation of clinical evidence demonstrating the drug’s safety profile and effectiveness in the pediatric population. This regulatory endorsement is particularly noteworthy given the heightened scrutiny applied to medications intended for children, where safety considerations are paramount and regulatory agencies typically demand robust, high-quality evidence before granting approval.

The Broader Implications for Pediatric Oncology

Norgine’s success in bringing PEDMARQSI® to the Australian market represents more than a single product registration. It signals growing recognition within the healthcare industry that supportive care innovations deserve the same attention and investment as primary cancer-fighting therapies. Quality of life for pediatric cancer survivors has become an increasingly central consideration in treatment decisions, and regulatory approvals like this one validate that approach.

For Australian pediatric oncology centers, hospitals, and clinics, PEDMARQSI® availability opens new possibilities for treatment planning. Physicians can now counsel families with greater optimism, explaining that modern oncology offers tools not only to fight cancer but also to prevent its treatment-related complications. This expanded therapeutic armamentarium may influence how clinicians approach cisplatin-containing regimens, potentially enabling more aggressive or prolonged chemotherapy when clinically indicated, knowing that hearing protection is available.

Looking Forward in Pediatric Cancer Care

The Australian TGA registration of PEDMARQSI® demonstrates the continued evolution of supportive oncology—the critical field focused on managing treatment side effects and preserving quality of life in cancer patients. As healthcare systems worldwide prioritize holistic patient outcomes rather than focusing narrowly on tumor response, approvals like this one reflect a maturation of cancer care philosophy.

For the families of Australian children diagnosed with solid tumors requiring cisplatin chemotherapy, this development offers genuine hope. While cancer remains a formidable adversary, the tools available to fight it while protecting children’s future hearing—and thereby their communication, learning, and social development—continue to expand. Norgine’s successful navigation of the regulatory pathway in Australia positions PEDMARQSI® as a crucial addition to pediatric oncology practice, ultimately improving outcomes and quality of life for some of medicine’s most vulnerable patients.